What is Janux Therapeutics, Inc. (JANX)?

Janux Therapeutics, Inc. (JANX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of JANX?

The current price of JANX is $18.05. Prices are updated in real time on Stocks360.

What is JANX's price-to-earnings (PE) ratio?

JANX's trailing twelve-month PE ratio is -10.94, based on current price and earnings per share data available on Stocks360.

What is JANX's market capitalization?

JANX's market capitalization is $1,103,518,753.00, placing it in the small-cap tier.

Janux Therapeutics, Inc. (JANX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$18.05

Market Cap

$1.10B

PE (TTM)

-10.94

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

2.39

Day Range

$17.01 – $18.07

52-wk Range

$12.12 – $35.34

Avg Volume

N/A

Volume

984.10K

Janux Therapeutics, Inc. (JANX) is a publicly traded company in the Healthcare sector. Latest price: $18.05. Market cap $1.10B. Trailing PE -10.94. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $27.81 2026-10-28 · $18.05 (-35.10%)

Earnings

Most Recent

Aug 6, 2026

EPS $-0.35 vs est. $-0.25

Missed by $0.10

Next Earnings

Nov 5, 2026

EPS estimate $-0.47

Proprietary Signals

Signal snapshot temporarily unavailable.

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-10.94×
P/S (TTM)	45.98×
P/B	1.22×
P/FCF (TTM)	-26.32×
EV / EBITDA	-10.89×
EV / Sales	45.70×
Earnings Yield	-9.03%
Free Cash Flow Yield	-3.80%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.10B
Revenue (TTM)	$24.00M
Net Income (TTM)	-$99.66M
Free Cash Flow (TTM)	-$41.92M
Net Debt	-$6.78M
Working Capital	$923.18M
Gross Margin	100.00%
Operating Margin	-598.15%
Net Margin	-427.47%
Return on Equity	-10.79%
Return on Invested Capital	-15.11%